Patent · US Active

Soluble ST2 as a marker for risk of mortality in HIV-infected subjects

US9804172B2 · kind B2 · utility

0Cited by

1References

6Claims

0Family size

Assignees

Institut National de la Sante et de la Recherche Medicale (INSERM) · FR
Université Paris—Est Créteil Val de Marne · FR
ASSISTANCE PUBLIQUE—HÔPITAUX DE PARIS (APHP) · FR

Inventors

Yves Levy · Malakoff, FR
Sophie Hue · Créteil, FR
Jean-Daniel Lelievre · Créteil, FR

Key dates

Filing date	Dec 14, 2012
Grant date	Oct 31, 2017
Priority date	—
Expiry date	Dec 14, 2032

Classification

Technology area (CPC G)Physics
CPC primaryG01N2800/32
WIPO fieldMeasurement
WIPO sectorInstruments

Abstract

The present invention relates to materials and methods concerning the IL-1 receptor family protein ST2. Use of soluble ST2 as a marker for cardiovascular disease or disease outcome is provided, in particular as a marker of the risk of mortality.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.